News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Researchers Target Mesothelioma Cells in Mice
- Malignant Pleural Mesothelioma and Chemotherapy wi...
- Medicare Widens Drugs It Accepts for Cancer
- Asbestos and Nanomaterials
- Pleural Mesothelioma and Surgery
- EPA Provides $2.1 Million Grant for Asbestos Resea...
- Mesothelioma Specialist in Hawaii Awarded Grants t...
- Cancer Drug Inventor Donates $1M for Student/Facul...
- Asbestos Disease Awareness Organization (ADAO) Awa...
- Implant Raises Cellular Army to Attack Cancer
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
Monday, March 2, 2009
Source: Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of MesotheliomaMorphotek has announced the beginning of a phase II clinical trial investigating the efficacy of the monoclonal antibody MORAb-009 for the treatment of mesothelioma. The study will evaluate progression-free survival in patients with advanced pleural mesothelioma who are being receiving MORAb-009 in combination with the standard mesothelioma treatment regimen, pemetrexed + cisplatin. The study will also analyze the “safety and anti-tumor activity of MORAb-009 as determined by objective response rate.” Morphotek plans on enrolling more than eighty individuals into the study, which is being conducted at multiple treatment centers around the word.
MORAb-009 is a monoclonal antibody whose mechanism of action inhibits the expression of mesothelin, which is a cell-surface protein highly expressed in mesothelioma, pancreatic cancer and a number of other malignant conditions.
Labels: mesothelioma, pleuralmesothelioma, treatments
posted by Joseph DiCastro at 2:16 PM
